Digital Spatial Profiling segmentation by application delineates four principal use‑cases: Oncology, Immunology, Neuroscience, and Infectious Diseases. Oncology dominates the market, accounting for roughly 45 % of total revenue, driven by the high prevalence of cancer, demand for tumor micro‑environment characterization, and extensive clinical‑trial pipelines. Immunology follows with an estimated 30 % share, reflecting growing investments in immune‑oncology, autoimmune‑disease research, and checkpoint‑inhibitor development, where spatial context of immune cells is critical. Neuroscience, contributing about 15 %, benefits from rising interest in brain‑region‑specific proteogenomic mapping to elucidate neurodegenerative pathways. Infectious Diseases, though smaller at 10 %, is gaining traction as spatial profiling aids in host‑pathogen interaction studies and vaccine design. Collectively, these application segments shape the overall Digital Spatial Profiling market size by allocating R&D budgets, influencing instrument sales, and guiding service‑provider strategies, underscoring the importance of a nuanced market taxonomy.